Efficacy and safety of an intravenous monoclonal anti‐HBs ...Wiley Online Library
onlinelibrary.wiley.com
von AB Van Nunen · · Zitiert von: 19 — Jens-Peter Marschner,. Jens-Peter Marschner. Department of Clinical Development, Boehringer Mannheim GmbH, Mannheim, Germany. Search for more ... von AB Van Nunen · · Zitiert von: 19 — Jens-Peter Marschner,. Jens-Peter Marschner. Department of Clinical Development, Boehringer Mannheim GmbH, Mannheim, Germany. Search for more ...
CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By ...ScienceDirect.com
www.sciencedirect.com
von X Zhao · · Zitiert von: 5 — ... Jens-Peter Marschner , MD,*,3 Martin Treder ,*,3 Holbrook Kohrt , MD4 1Center for Clinical Sciences Research Stanford, Stanford University ... von X Zhao · · Zitiert von: 5 — ... Jens-Peter Marschner , MD,*,3 Martin Treder ,*,3 Holbrook Kohrt , MD4 1Center for Clinical Sciences Research Stanford, Stanford University ...
Specific NK Cell Activation to Treat Relapsed/Refractory (r/ ...ScienceDirect.com
www.sciencedirect.com
von A Rothe · · Zitiert von: 2 — ... Jens-Peter Marschner, MD,*,8 Andreas Engert, MD9 1University Hospital of Cologne, Cologne, Germany 2University Hospital of Cologne, Cologne ... von A Rothe · · Zitiert von: 2 — ... Jens-Peter Marschner, MD,*,8 Andreas Engert, MD9 1University Hospital of Cologne, Cologne, Germany 2University Hospital of Cologne, Cologne ...
Journal of Translational MedicineCORE
core.ac.uk
von BA Fox · · Zitiert von: 187 — Jens-Peter Marschner (). Michael J Mastrangelo (). Giuseppe Masucci (giuseppe ... von BA Fox · · Zitiert von: 187 — Jens-Peter Marschner (). Michael J Mastrangelo (). Giuseppe Masucci (giuseppe ...
Alle Infos zum Namen "Jens-Peter Marschner"
A phase 1 study of the bispecific anti-CD30/CD16A ...Europe PMC
europepmc.org
von A Rothe · · Zitiert von: 307 — ... Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Find articles by Jens-Peter Marschner. Elke Pogge von Strandmann. 2Innate Immunity Group, Department I of ... von A Rothe · · Zitiert von: 307 — ... Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Find articles by Jens-Peter Marschner. Elke Pogge von Strandmann. 2Innate Immunity Group, Department I of ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...Europe PMC
europepmc.org
von CR Lemech · · Zitiert von: 13 — ... Jens-Peter Marschner. 3Therapim Pty Ltd, Southport, QLD Australia. Find articles by Jens-Peter Marschner. Konstantinos Alevizopoulos. 3Therapim Pty Ltd ... von CR Lemech · · Zitiert von: 13 — ... Jens-Peter Marschner. 3Therapim Pty Ltd, Southport, QLD Australia. Find articles by Jens-Peter Marschner. Konstantinos Alevizopoulos. 3Therapim Pty Ltd ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von CR Lemech · · Zitiert von: 13 — Jens-Peter Marschner , Konstantinos Alevizopoulos , Marit Otterlei , Michael Millward. Affiliations. 1 Scientia Clinical Research ... von CR Lemech · · Zitiert von: 13 — Jens-Peter Marschner , Konstantinos Alevizopoulos , Marit Otterlei , Michael Millward. Affiliations. 1 Scientia Clinical Research ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...The University of Western Australia
research-repository.uwa.edu.au
von CR Lemech · · Zitiert von: 13 — Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward · Internal ... von CR Lemech · · Zitiert von: 13 — Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward · Internal ...
Defining the critical hurdles in cancer immunotherapy.Europe PMC
europepmc.org
von BA Fox · · Zitiert von: 187 — ... Jens-Peter Marschner,68 Michael J Mastrangelo,69 Giuseppe Masucci,70 Ignacio ... Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro ... von BA Fox · · Zitiert von: 187 — ... Jens-Peter Marschner,68 Michael J Mastrangelo,69 Giuseppe Masucci,70 Ignacio ... Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro ...
New Approaches in Immunotherapy for the Treatment ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von S Quaratino · · Zitiert von: 15 — Authors. Sonia Quaratino , Ulf Forssmann , Jens-Peter Marschner. Affiliations. 1 Kymab Ltd, The Bennet Building (B930), Babraham Research Campus ... von S Quaratino · · Zitiert von: 15 — Authors. Sonia Quaratino , Ulf Forssmann , Jens-Peter Marschner. Affiliations. 1 Kymab Ltd, The Bennet Building (B930), Babraham Research Campus ...
Pre-Clinical Chemotherapy and Biologic Agents: Poster IIThe Conference Exchange
ash.confex.com
von X Zhao · · Zitiert von: 1 — ... Jens-Peter Marschner, MD3*, Martin Treder3* and Holbrook Kohrt, MD4. 1Center for Clinical Sciences Research Stanford, Stanford University ... von X Zhao · · Zitiert von: 1 — ... Jens-Peter Marschner, MD3*, Martin Treder3* and Holbrook Kohrt, MD4. 1Center for Clinical Sciences Research Stanford, Stanford University ...
Updated phase I data of AFM13: A bispecific tandem ...ASCO Publications
ascopubs.org
von A Rothe · · Zitiert von: 2 — Hummel, Miroslav Ravic, Jens-Peter Marschner, and Andreas EngertAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 32, Number ... von A Rothe · · Zitiert von: 2 — Hummel, Miroslav Ravic, Jens-Peter Marschner, and Andreas EngertAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 32, Number ...
Verwandte Suchanfragen zu Jens-Peter Marschner
sortiert nach Relevanz / Datum